Zobrazeno 1 - 10
of 17 952
pro vyhledávání: ''
Autor:
Lajos Pusztai, Gabriel N. Hortobagyi, Bryan T. Hennessy, Massimo Cristofanilli, Chafika Mazouni, Fabrice Andre, Attila Tordai, W. Fraser Symmans, Cornelia Liedtke, Marjorie C. Green, Ana M. Gonzalez-Angulo, Kenneth R. Hess, Jaime A. Mejia
Publikováno v:
Journal of Clinical Oncology. 41:1809-1815
PURPOSE Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. In this study, we compared response to neoadjuvant chemotherap
Publikováno v:
Leukemia & Lymphoma. 63:2428-2435
Mycosis Fungoides (MF) is a rare T-cell lymphoma and evidence on treatment practices, and outcomes are limited. We evaluated changes in practice patterns and corresponding effects on overall survival (OS) in MF using a cross-sectional study of patien
Autor:
David M. O'Malley, Maryna Neffa, Bradley J. Monk, Tamar Melkadze, Marilyn Huang, Anna Kryzhanivska, Iurie Bulat, Tarek M. Meniawy, Andrea Bagameri, Edward W. Wang, Bernard Doger de Speville Uribe, Roberto Hegg, Waldo Ortuzar Feliu, Marek Ancukiewicz, Iwona Lugowska
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(7)
PURPOSE Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte–associated antigen-4) are two new checkpoint inhibitors emerging as promising investigational agents for the treatment of advanced cervical cancer. This phase
Autor:
En Cheng, Fang-Shu Ou, Chao Ma, Donna Spiegelman, Sui Zhang, Xin Zhou, Tiffany M. Bainter, Leonard B. Saltz, Donna Niedzwiecki, Robert J. Mayer, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Edward L. Giovannucci, Erin L. Van Blarigan, Justin C. Brown, Kimmie Ng, Cary P. Gross, Jeffrey A. Meyerhardt, Charles S. Fuchs
Publikováno v:
J Clin Oncol
PURPOSE Current tools in predicting survival outcomes for patients with colon cancer predominantly rely on clinical and pathologic characteristics, but increasing evidence suggests that diet and lifestyle habits are associated with patient outcomes a
Autor:
Hiroshi Kobayashi, Liuzhe Zhang, Toshihide Hirai, Yusuke Tsuda, Masachika Ikegami, Sakae Tanaka
Publikováno v:
Japanese Journal of Clinical Oncology. 52:589-598
Background Clinical characteristics of undifferentiated pleomorphic sarcoma of bone are not elucidated. Herein, we clarify its clinical features and analyze the efficacy of adjuvant chemotherapy in patients with undifferentiated pleomorphic sarcoma o
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
BMC cancer, 22(1):130
BMC Cancer
BMC cancer, 22(1):130
BMC Cancer
BackgroundWe aimed to explore the potential of German claims data for describing initial and long-term treatment patterns of breast cancer patients undergoing surgery.MethodsUsing the German Pharmacoepidemiological Research Database (GePaRD, ~ 20% of
Autor:
Kiki C. Andree, Menno Tamminga, Harry J.M. Groen, T. Jeroen N. Hiltermann, Ed Schuuring, Leon W.M.M. Terstappen, Anouk Mentink, Hilda van den Bos, Peter M. Lansdorp, Wim Timens, Diana C.J. Spierings
Publikováno v:
British journal of cancer, 126, 409-418. Nature Publishing Group
Br J Cancer
British Journal of Cancer, 126. Nature Publishing Group
Br J Cancer
British Journal of Cancer, 126. Nature Publishing Group
BACKGROUND: Circulating tumour cells (CTCs) can be used to monitor cancer longitudinally, but their use in non-small cell lung cancer (NSCLC) is limited due to low numbers in the peripheral blood. Through diagnostic leukapheresis (DLA) CTCs can be ob
Autor:
Chana Weinstock, Laleh Amiri-Kordestani, Xiao Hong Chen, Elaine Chang, Eias Zahalka, Jeanne Fourie Zirkelbach, Shenghui Tang, Amna Ibrahim, Mallorie H. Fiero, Julia A. Beaver, Kirsten B. Goldberg, Vishal Bhatnagar, Miao Zhao, Paul G. Kluetz, Richard Pazdur, Tiffany K. Ricks, Jingyu Yu, Junshan Qiu, Lijun Zhang
Publikováno v:
Clin Cancer Res
On March 10, 2021, the FDA granted regular approval to tivozanib for treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. Approval was based on the TIVO-3 study, a
Autor:
C. Meyer, Y. Fouché, Emmanuel Chamorey, M. Dejode, C. Bailleux, J. Haudebourg, Renaud Schiappa, Y. Delpech, Emmanuel Barranger
Publikováno v:
Clinical Breast Cancer. 22:121-126
Background Delays in initiating adjuvant chemotherapy after breast cancer surgery seems to have an impact on patients’ risk of relapse and their survival rate. The aim of this retrospective study was to identify factors delaying initiation of adjuv
Publikováno v:
Future Oncology
Introduction: The objective of this study was to evaluate the clinical and laboratory outcomes of solid cancer patients who were reinfected with COVID-19. Methods: Patients who were tested negative on the Coronavirus disease 2019 (COVID-19) PCR test